|
Annoesjka was an active and enthusiast member of several long-term national and international Steering Committees such as:  | European Regulatory Issues on Quality of Life Assessment Group , from 1997 to 2004.
Goal: The acceptance of Patient Reported Outcomes in drug registration and labelling. Results: The FDA Guidance on PROs in labelling and the EMEA reflection paper are results of this process as well as publications updating the professional anena |  | Assessing treatment impact using PROs: Challenges in study design, conduct and analysis, Paris, 2004
Goal: Inform professionals on the status of PRO assessment in relation to registration and labelling.
Results: A well-attended and valued DIA workshop . |  | Farmaco Economics working group of the Dutch Association of Innovative Pharmaceutical Industry (NEFARMA), from 2000 to 2004.
Goal: Follow-up on the Pharmaco Economic Guidelines of 1999. Results: Development of the NVD database in which the Dutch reimbursement practicea are recorded in order to inform policy discussions with the Ministry of Health Care and the Health Care Insurance Board (CVZ). | | Funding working group for Expensive Hospital Medicines of the Dutch Association of Innovative Pharmaceutical Industry (NEFARMA), from 2004 to 2008. Goal: Fast and complete funding of Expensive Hospital Medicines. Results: A visiondocument from the Innovative Pharma Industry was developed as input for the guidance on Real-World Outcomes Research for the conditional reimbursement of hospital medicines. Annoesjka was invited to present the Industry view during a meeting by the Health Care Insurance Board in September 2006 |
|
